Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer – The NORDIC-VII Study
: The NORDIC-VII Study
: Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T
Publisher: AMER SOC CLINICAL ONCOLOGY
: 2012
: Journal of Clinical Oncology
: JOURNAL OF CLINICAL ONCOLOGY
: J CLIN ONCOL
: 30
: 15
: 1755
: 1762
: 8
: 0732-183X
DOI: https://doi.org/10.1200/JCO.2011.38.0915
Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC. J Clin Oncol 30:1755-1762. (c) 2012 by American Society of Clinical Oncology